Thromboembolism prevention after chronic subdural hematoma in the elderly: A leap in the dark.

Neurology

From the Division of Vascular Neurology and Neurocritical Care (J.I.S.), Department of Neurology, Baylor College of Medicine, CHI Baylor St Luke's Medical Center, Houston, TX; and Departments of Neurosurgery & Neurology (G.K.), Hofstra Northwell School of Medicine, Manhasset, NY.

Published: May 2017

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000003923DOI Listing

Publication Analysis

Top Keywords

thromboembolism prevention
4
prevention chronic
4
chronic subdural
4
subdural hematoma
4
hematoma elderly
4
elderly leap
4
leap dark
4
thromboembolism
1
chronic
1
subdural
1

Similar Publications

This case report describes the management of a 30-year-old male patient with a history of an advanced nonseminomatous germ cell tumor, hip fracture complicated by extensive deep vein thrombosis and pulmonary embolism, and on apixaban presenting with asymptomatic intracardiac teratoma and abdominopelvic metastases. Multidisciplinary intervention, including successful surgical excision of the intracardiac mass, highlights the importance of coordinated care and vigilant follow-up in optimizing patient outcomes and preventing life-threatening complications.

View Article and Find Full Text PDF

CYP2C19 Genotype-Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure.

Clin Transl Sci

January 2025

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

In neurovascular settings, including treatment and prevention of ischemic stroke and prevention of thromboembolic complications after percutaneous neurointerventional procedures, dual antiplatelet therapy with a P2Y12 inhibitor and aspirin is the standard of care. Clopidogrel remains the most commonly prescribed P2Y12 inhibitor for neurovascular indications. However, patients carrying CYP2C19 no-function alleles have diminished capacity for inhibition of platelet reactivity due to reduced formation of clopidogrel's active metabolite.

View Article and Find Full Text PDF

Background:  The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism (VTE) in clinical practice are not well understood.

Methods:  ETNA-VTE Europe is a prospective, noninterventional, post-authorization study in unselected patients with VTE treated with edoxaban in eight European countries for up to 18 months. Recurrent VTE, major bleeding, and all-cause death were the primary study outcomes.

View Article and Find Full Text PDF

Background: The rate of VTE in trauma patients varies significantly in the reported literature. We aimed to determine the incidence of VTE in trauma patients in a trauma-receiving hospital over a 7-year period. We sought to evaluate the timing and nature of VTE events and explore the patterns of co-occurrence between PE and DVT, while factoring in clinical care and death outcome.

View Article and Find Full Text PDF

Background: Plant-based dietary patterns are becoming increasingly popular due to environmental and health impacts, yet there are few studies exploring the relationship between plant-based dietary patterns and venous thromboembolism (VTE) in different genetic backgrounds.

Objectives: The aim of this study was to investigate how plant-based dietary pattern and genetic susceptibility independently or jointly affect VTE and its subtypes of pulmonary embolism and deep vein thrombosis.

Methods: A total of 183,510 participants who were White British ethnicity background and free of VTE at baseline in the UK Biobank were recruited, in consideration that the selection of genetic variants for VTE was based on results of White European individuals.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!